
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Refractory patients, biomarkers, and regulatory opportunities
Richard says soquelitinib worked in prior‑therapy failures and that actionable biomarkers remain elusive.
Play episode from 12:44
Transcript


